Table 3.
Characteristics of identified neoantigen-specific T cell responses in TIL infusion products
| Gene mutation | WT peptide | Mutant peptide | Frequency (% multimer+CD8+ T cells of total CD8+ T cells) | Restriction element | |
| Patient 3 | RBM12 S>L | SPHEAGFCV | LPHEAGFCV | 29.00 | HLA-B*51:01 |
| VARS T>M | EVADEATGAL | EVADEAMGAL | 0.096 | HLA-A*25:01 | |
| MYLK G>V | EVFPEDTGTY | EVFPEDTVTY | 1.90 | HLA-A*25:01 | |
| LRP3 T>S | LTAARPSQTVL | LTAARPSQSVL | 0.039 | HLA-A*25:01 | |
| WDR1 N>K | DSFAGKGHTN | DSFAGKGHTK | 0.50 | HLA-A*68:01 | |
| Patient 4 | TTC37 A>V | YLDGKAVDY | YLDGKVVDY | 1.14 | HLA-A*01:01 |
| ENTPD4 P>L | ATDTNNPNVNY | ATDTNNLNVNY | 3.35 | HLA-A*01:01 | |
| MAB21L1 V>M | LRIRDRYVV | LRIRDRYVM | 0.007 | HLA-B*08:01 | |
| Patient 8 | RAD51AP1-002 S>F | KVKSPVEKK | KVKFPVEKK | 0.195 | HLA-A*03:01 |
TIL, tumor infiltrating lymphocyte.